#Sweden #Stockholm #Sobi #gout #NASP

FDA Acceptance of Sobi's NASP for Uncontrolled Gout

Sobi®, a prominent biopharmaceutical company, has achieved a significant milestone in the treatment of uncontrolled gout by receiving the FDA's acceptance of its Biologics License Application (BLA) for a novel therapy known as NASP. This groundbreaking treatment combines two investigational agents: nanoencapsulated sirolimus and pegadricase, administered every four weeks through infusion. With the Prescription Drug User Fee Act (PDUFA) target action date set for June 27, 2026, many patients are looking towards NASP as a potential solution to their unmet healthcare needs.

What is NASP?

NASP, previously identified by the code SEL-212, is not just another treatment option; it represents a significant innovation in the management of gout. The therapy aims to address chronic inflammation that people with uncontrolled gout experience, a condition that can lead to debilitating flares, tophi formation, and various comorbid health issues, adversely impacting the overall quality of life.

Dr. Lydia Abad-Franch, Chief Medical Officer at Sobi, emphasizes the unmet needs of this patient population. Over 200,000 individuals in the U.S. are diagnosed with uncontrolled gout, enduring high serum uric acid (sUA) levels despite available oral treatments. In this context, NASP is positioned as a potential game-changer by targeting both the causes and symptoms of the ailment.

Clinical Trial Successes

The acceptance of the BLA was bolstered by promising results from Phase 3 DISSOLVE I and II clinical trials. Both studies evaluated NASP's safety and effectiveness in adult patients suffering from uncontrolled gout, and both met their primary endpoints. The trials demonstrated that a significant percentage of participants achieved and maintained a reduction in sUA levels below 6 mg/dL, highlighting the therapy's efficacy in the management of the disease.

In DISSOLVE I, an impressive 51% response rate was recorded in patients receiving the higher dose of NASP, while 43% of participants in the lower dose group experienced similar benefits. Furthermore, simultaneous reductions in gout flares and tophi, as well as improvements in patient-reported quality of life metrics, were observed throughout the study duration. Additionally, NASP was generally well-tolerated across all dose levels, indicating a favorable safety profile.

FDA's Fast Track Designation

Recognizing NASP’s immense potential, the FDA granted it Fast Track designation in May 2024. This status allows for expedited review and development of drugs addressing serious conditions with significant unmet needs. For patients with uncontrolled gout, this designation represents hope for a more effective therapeutic option that could vastly improve their day-to-day lives.

Understanding Uncontrolled Gout

Gout, recognized as the most common form of inflammatory arthritis, impacts over 8.3 million individuals in the United States alone. Characterized by painful flares that result from elevated levels of uric acid, the condition is not only painful but can be associated with other serious health concerns impacting the heart, kidneys, and metabolic function. Thus, finding effective treatments like NASP that can alleviate symptoms and improve sUA levels is essential in promoting overall well-being for these patients.

Final Thoughts

As Sobi continues to advance the development of NASP, the company underscores its commitment to addressing the unmet healthcare requirements of people living with rare diseases. The innovative combination of nanoencapsulated sirolimus and pegadricase may not only transform the landscape of gout treatment but also provide invaluable relief to those struggling with this debilitating condition. Patients and healthcare professionals alike are poised to witness a new dawn in gout management as Sobi embarks on the next steps towards bringing NASP to market.